Trial Profile
An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease
- 02 Mar 2022 Planned number of patients changed from 2000 to 3000.
- 02 Mar 2022 Planned End Date changed from 1 Dec 2025 to 31 Dec 2025.
- 02 Mar 2022 Planned primary completion date changed from 1 Dec 2023 to 31 Dec 2023.